Halo Biologics

Halo Biologics is a biotechnology company based in Bristol, UK, specializing in the development of programmable biologics to treat viral infections. A spin-out from the University of Bristol, the company utilizes its proprietary Halo platform to target a highly conserved linoleic acid binding pocket (the "Halo pocket") on the spike protein of coronaviruses. This approach locks the virus in a non-infectious state, potentially offering a pan-variant solution for COVID-19 and other emerging coronaviruses. The company's technology aims to provide a robust defense against viral mutations by targeting a site essential for viral function. Halo Biologics is currently in the pre-clinical stage, focusing on optimizing its lead candidates for clinical entry. The company is backed by specialized life science investors and leverages world-class structural biology expertise.